About James Tananbaum
James Tananbaum is a director and 10% owner at Latigo Biotherapeutics.
Form D filings also name James Tananbaum as a director at Alumis.
James Tananbaum reports to the SEC as a director, officer or major shareholder of 13 public companies, including Alumis (ALMS), Kinnate Biopharma (KNTE) and Pardes Biosciences (PRDS).
James Tananbaum first appears on SEC filings in 2013.
Experience
This experience comes from SEC filings. The years are when the filings name James Tananbaum in the role, so the role may have started earlier or lasted longer.
KI
Kinnate Biopharma Inc.
Director and 10% owner
2020 – 2024 · Public company (KNTE)
PI
Pardes Biosciences, Inc.
President and CEO, director
2021 – 2023 · Public company (PRDS)
TI
Theseus Pharmaceuticals, Inc.
10% owner
2022 – 2023 · Public company (THRX)
AI
Aclaris Therapeutics, Inc.
10% owner
2021 · Public company (ACRS)
DI
Disc Medicine, Inc.
President & CEO, director
2020 – 2021 · Public company (IRON)
QI
Quantum-Si Inc
Director
2021 · Public company (QSI)
1I
10x Genomics, Inc.
10% owner
2019 – 2020 · Public company (TXG)
AI
Aerie Pharmaceuticals Inc.
10% owner
2016 – 2020 · Public company (AERI)
AI
Aimmune Therapeutics, Inc.
10% owner
2015 – 2016 · Public company (AIMT)
II
Intellia Therapeutics, Inc.
10% owner
2016 · Public company (NTLA)
AC
Ambit Biosciences Corp.
10% owner
2013 · Public company (AMBI)
Key Colleagues at Startups
The people James Tananbaum works with at each company, as listed on that company's latest Form D.
Latigo Biotherapeutics, Inc. · Form D, Feb 13, 2025
NS
Nancy Stagliano
Director
BS
Beth Seidenberg
Director
NF
Nima Farzan
Executive officer and director
DP
Deborah Palestrant
Director
KR
Kevin Raidy
Director
TL
Tim Lugo
Chief Financial Officer
TW
Tim Walbert
Director
Alumis Inc. · Form D, Jul 24, 2024
SA
Srinivas Akkaraju
Director
JS
John Schroer
Executive officer
DR
Derrick Richardson
Executive officer
PM
Patrick Machado
Director
SS
Sapna Srivastava
Director
MB
Martin Babler
CEO and director
MB
Mark Bradley
Executive officer
ZY
Zhengbin Yao
Director
SK
Sara Klein
Executive officer
DG
David Goldstein
Executive officer
JD
Jorn Drappa
Executive officer
AC
Alan Colowick
Director
RH
Roy Hardiman
Executive officer